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New DelhiCigarette smoking is a leading preventable risk factor for the development and progression of cardiovas-
cular diseases (CVDs). Epidemiologic studies conclusively prove that both active smoking and second-
hand smoke contribute signiﬁcantly to morbidity and mortality related to CVD. Cigarette smoke is a
mixture of several toxic chemicals, of which nicotine, carbon monoxide, and oxidant chemicals are most
commonly implicated in the pathogenesis of cardiovascular disease. Tobacco causes endothelial dys-
function, inﬂammation, insulin resistance, alteration of lipid proﬁle, hemodynamic alterations, and a
hypercoagulable state. All of these act synergistically as pathobiologic mechanisms of atherothrombosis
in tobacco users.Cigarette smoking is a leading preventable risk
factor for the development and progression of car-
diovascular diseases. Epidemiologic studies conclu-
sively prove that both active smoking and
secondhand smoke contribute significantly to mor-
bidity andmortality related to cardiovascular disease.
Cigarette smoke is a mixture of several toxic chemi-
cals, of which nicotine, carbon monoxide, and
oxidant chemicals are most commonly implicated
in the pathogenesis of cardiovascular disease. Tobac-
co smoking is associated with endothelial dysfunc-
tion, inflammation, insulin resistance, dyslipidemia,
hemodynamic alterations, and a hypercoagulable
state. All of these act synergistically as pathobiologic
mechanisms of atherothrombosis in tobacco users.
Smoking is a major cause of death from cardio-
vascular disease. Several epidemiologic studies
unequivocally prove that cigarette smoking in-
creases the incidence of coronary artery disease
(CAD) [1–6]. According to World Health Organi-
zation (WHO) estimates, nearly 5.4 million prema-
ture deaths a year are attributable to tobacco
smoking worldwide [7]. If current trends continue,Department of Cardiology, Cardiothoracic Sciences Centre, All
sease Control and Director, Center of Excellence in Cardio-met
, India. Correspondence: A. Roy (drambujroy@gmail.com).10 million smokers per year are anticipated to die by
2025 [8,9]. Approximately 35–40% of smoking-re-
lated deaths are due to cardiovascular diseases
[10,11]. Moreover, exposure to environmental to-
bacco smoke (secondhand smoke) poses a signifi-
cant cardiovascular health hazard. Secondhand
smoke has been shown to increase the risk of devel-
oping CAD by 25–30% [12]. Although the link be-
tween CAD and smoking is clear and conclusive,
the mechanisms by which it occurs are not com-
pletely understood. Several factors may be involved
because smoking has a variety of effects that may
contribute to thrombosis and atherogenesis. This
paper outlines the various postulated pathophysio-
logical mechanisms involved in tobacco-related
cardiovascular disease.
COMPONENT S O F C I GAR E T T E SMOK E
Tobacco smoke is a toxic mixture of more than
5,000 chemical compounds [13,14]. Cigarette
smoke is a complex aerosol consisting of vapor and
particulate phases [15]. The particulate phase isIndia Institute of Medical Sciences, New Delhi, India; and Centre for
abolic Risk Reduction in South Asia, Public Health Foundation of India,
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is passed through the cigarette filter, whereas the
vapor phase material passes through the filter. The
major vapor phase constituents include carbon
monoxide, acetaldehyde, formaldehyde, acrolein,
nitrogen oxides, and carbon dioxide, whereas nico-
tine and various particulate matters (collectively
known as ‘‘tar’’) constitute the major particulate
phase components of cigarette smoke. Terms com-
monly used to describe the smoke coming from a
cigarette are mainstream smoke, side stream smoke,
and secondhand or environmental tobacco smoke.
Cigarette smoke that is drawn through the tobacco
into an active smoker’s mouth is known as main-
stream smoke [16]. Side stream smoke describes
the smoke coming off the end of a smoldering cig-
arette. When combined, side stream smoke and a
small fraction of exhaled mainstream smoke form
secondhand smoke, also known as environmental
tobacco smoke. Side stream smoke contains a rela-
tively higher concentration of the toxic gaseous
component than mainstream cigarette smoke does.RO L E O F VAR I OU S COMPONENT S OF
TOBACCO SMOKE I N CARD I OVA S CU LAR
D I S E A S E
The constituents of cigarette smoke that have re-
ceived the greatest attention, as potential contribu-
tors to cardiovascular disease are nicotine, carbon
monoxide, and oxidant gases. There has also been
some research on polycyclic aromatic hydrocarbons
and other constituents of tobacco smoke that may
contribute to atherogenesis [17].
Nicotine.Nicotine, one of the most studied constit-
uents of cigarette smoke, is a potent ganglionic and
central nervous system stimulant. Each puff con-
tains approximately 50 lg of nicotine. Nicotine ex-
erts its cardiovascular effect via sympathetic neural
stimulation [18,19]. The hemodynamic effects of
cigarette smoking are mediated primarily by nico-
tine. Nicotine increases heart rate, blood pressure,
and cardiac output, leading to an increase in myo-
cardial oxygen demand. It increases heart rate both
acutely (up to 10–15 beats/min) [20], as well as
throughout the day with regular dosing (average
increase 7 beats/min as measured on ambulatory
monitoring) [17]. Whether nicotine plays a direct
role in the development of atherosclerosis is still
unclear. It has been reported to have variable effectson nitric oxide [21,22], which may contribute to
endothelial dysfunction in tobacco users [23].
Carbon monoxide. Carbon monoxide (CO) is in-
haled in cigarette smoke. Although previously
thought to be responsible for the adverse cardiovas-
cular effects of smoking, there is data to suggest
that CO from cigarette smoke may be an unlikely
cause for atherosclerosis or thrombosis [24]. In
healthy persons, CO in concentrations similar to
cigarette smoking does not affect blood pressure,
plasma catecholamines, platelet aggregation, or ser-
um C-reactive protein [25]. However, CO expo-
sure in patients with CAD can result in
significant adverse effects, including lower thresh-
olds for exercise-induced ischemia, ventricular dys-
function, and increased ventricular arrhythmias
[26].
Oxidant gases. Free radical-mediated oxidative
stress may play a central role in the development
of atherosclerosis. In a setting of cigarette smoking,
free radicals could arise from: (1) the vapor or par-
ticulate phases of cigarette smoke; (2) circulating or
in situ-activated macrophages and neutrophils;
and/or (3) endogenous sources of reactive oxygen
species such as uncoupled endothelial nitric oxide
synthase, xanthine oxidase, and the mitochondrial
electron transport chain [16]. Oxidizing chemicals,
including oxides of nitrogen and many free radicals,
present in high levels in cigarette smoke are the
prime mediators of endothelial dysfunction in
smokers. Smokers are known to have lower plasma
levels of antioxidants such as vitamin C and beta-
carotene [27,28]. There is some evidence to suggest
that administration of antioxidants such as vitamin
C may improve endothelial dysfunction in chronic
smokers [29].
Apart from these, cigarette smoke contains a
number of metals, including aluminum, cadmium,
copper, lead, mercury, nickel, and zinc, which cat-
alyze the oxidation of cellular proteins and may
lead to structural cellular damage and endothelial
dysfunction. Acrolein, a reactive aldehyde produced
by endogenous lipid peroxidation, is present in
high levels in cigarette smoke. It adversely modifies
apolipoprotein A-1 [30], the major protein in
high-density lipoprotein (HDL), and leads to oxi-
dation of prominent cellular antioxidant proteins
called thioredoxins in endothelial cells, which can
lead to endothelial cell death and dysfunction
[31]. Polycyclic aromatic hydrocarbons found in
the tar fraction of cigarette smoke are reported to
Figure 1. Overview of the various pathophysiological mechanisms of tobacco in the development of cardiovascular disease. BP,
blood pressure; HR, heart rate; NO, nitric oxide.
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[32].PA THOPHY S I O LOG I C MECHAN I SMS O F
TOBACCO SMOKE I N CARD I OVA S CU LAR
D I S E A S E
Epidemiological studies have conclusively proven
the relationship between smoking and CAD. The
pathobiologic mechanisms behind this link, how-
ever, are not clearly understood. Tobacco affects
several known pathophysiological pathways leading
to the development of atherothrombosis (Fig. 1).
Vascular and endothelial dysfunction. Smoking
can damage the vascular wall, leading to impaired
prostacyclin production and enhanced platelet-ves-
sel wall interactions [33]. This can reduce the elas-
tic properties of the aorta, resulting in stiffening
and trauma to the wall [34]. Smoking, including
secondhand smoke, impairs endothelium-depen-
dent vasodilation of normal coronary arteries and
reduces coronary flow reserve [35,36]. Smoking is
also a risk factor for coronary vasospasm [37].The effect on endothelial function results primarily
from oxidative chemicals with enhanced oxidation
of low-density lipoprotein (LDL) and reduced
generation of nitric oxide [38–40].
Inﬂammation. Inflammation plays a major role in
the pathogenesis of atherosclerosis. Cigarette
smoking is associated with evidence of chronic
inflammation. Studies have shown that smoking
causes a 20–25% increase in the peripheral blood
leukocyte count [15] and an increased level of mul-
tiple inflammatory markers including interleukin-
6, C-reactive protein, and tumor necrosis factor al-
pha [41,42]. Elevations of various proinflammatory
cytokines increase leukocyte–endothelial cell inter-
action leading to leukocyte recruitment, which is
an early event in atherosclerosis [16]. Indeed, solu-
ble vascular cell adhesion molecule 1, intracellular
adhesion molecule 1, and E-selectin levels have
been found to be higher in smokers [43]. The
Northwick Park Heart Study and MONICA
(Monitoring Trends and Determinants in Cardio-
vascular Disease) study demonstrated elevated ser-
um fibrinogen levels, an acute phase reactant, in
smokers that reached normal levels within 5 years
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viduals who participated in the NHANES III
(Third National Health and Nutrition Examina-
tion Survey), Bakhru and Erlinger [46] demon-
strated that inflammatory markers, including C-
reactive protein, fibrinogen, white cell count, and
albumin, demonstrated a dose-dependent and tem-
poral relationship to smoking and smoking cessa-
tion [46]. In their study, these inflammatory
markers returned to baseline levels 5 years after
smoking cessation, suggesting that the inflamma-
tory component of cardiovascular disease resulting
from smoking may be reversible with reduced to-
bacco exposure and smoking cessation.
Prothrombotic state. Cigarette smoking is well
known to induce a prothrombotic state, as exempli-
fied by higher rates of acute myocardial infarction
and sudden death as compared to angina pectoris,
in smokers [31,47]. Smoking exerts a prothrom-
botic state through several pathogenic mechanisms
including alteration of thrombotic factors, fibrino-
lytic factors, and platelet-mediated pathways.
Cigarette smoking leads to elevations in fibrino-
gen concentration [48] and increased expression of
tissue factor [49]. It induces alteration of fibrinolysis
by inhibition of tissue plasminogen activator release
from the endothelium and increase in plasminogen
activator inhibitor-1 levels [50]. Additionally,
platelet-mediated pathways of thrombosis are also
activated, with platelets isolated from chronic
smokers having an increased propensity to stimu-
lated as well as spontaneous aggregation [51,52].
Smoking is associated with increased platelet-
dependent thrombin generation [53]. Cigarette
smoking may decrease the availability of platelet-
derived nitric oxide and decrease platelet sensitivity
to exogenous nitric oxide, leading to increased acti-
vation and adhesion [54,55]. Carbon monoxide-in-
duced relative hypoxemia leads to higher red cell
mass, causing increase in blood viscosity, which also
predisposes to thrombosis.
Effect on lipid proﬁle. Compared with nonsmokers,
smokers have been found to have higher levels of
serum cholesterol, triglycerides, very low-density
lipoprotein cholesterol, low-density lipoprotein
cholesterol (LDL-C), and lower serum concentra-
tions of high-density lipoprotein cholesterol
(HDL-C) and apolipoprotein A-1 [56]. A recent
randomized trial revealed that smoking cessation
improved total HDL, and large HDL particles,
but did not affect LDL-C levels or LDL size
[57]. Several studies have shown that cigarette
smoking enhances oxidative modification of plasmaLDL-C, which may be proatherogenic and has
been shown to impair endothelial function [58–
60].
Smoking and insulin-resistance/metabolic
syndrome. Compared to nonsmokers, smokers
have been demonstrated to be more insulin-resis-
tant and hyperinsulinemic [61]. Cigarette smok-
ing is a risk factor for the development of type-
2 diabetes [62]. This increased risk declines after
smoking cessation. Smokers, compared with non-
smokers, with diabetes have higher hemoglobin
A1C levels, require more insulin, and have in-
creased risk of microvascular and macrovascular
complications of diabetes. Smoking by enhancing
insulin resistance, central obesity, and dyslipide-
mia increases the risk of incident metabolic syn-
drome [63]. There is increasing evidence that
smoking causes greater accumulation of visceral
fat. Several cross-sectional studies indicate that
waist/hip ratio is higher in smokers than in non-
smokers [64,65]. Waist/hip ratio is positively
associated with the number of pack-years of
smoking, and there is a dose–response relation be-
tween waist/hip ratio and the number of cigarettes
smoked [66].
The mechanistic link between cigarette smoking
and insulin resistance is not fully established, but
there is evidence for a role of nicotine. Activation
of the sympathetic nervous system and release of
corticosteroids and growth hormone by nicotine
may contribute to insulin resistance. Insulin resis-
tance has been shown to adversely alter lipid profile
[67,68], cause endothelial dysfunction, and increase
oxidative stress [69], leading to the development of
cardiovascular disease.
Genetic factors. Genes have been shown to influ-
ence smoking behavior, affect the metabolism of
nicotine and specific chemicals produced during
combustion, and enhance (or diminish) patho-
mechanistic pathways associated with the athero-
genic potential of smoking, including oxidative
stress, its inflammatory burden, or procoagulant
potential [70]. Studies have shown the interaction
between heavy smoking and glutathione-S-trans-
ferase theta genotype GSTT1-1 and its relation
to pre-clinical atherosclerosis in the form of in-
creased intima-media thickness [71]. Recently, it
was shown that the CYBA gene A640G polymor-
phism might influence individual predispositions
to CAD through interactions with smoking and
hypercholesterolemia [72,73]. Although several
candidate genes and their genetic variants have
been associated with atherosclerosis and cigarette
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and association cannot be made.NONC I GAR E T T E TOBACCO PRODUCT S
Smokeless tobacco. Smokeless tobacco products
consist of tobacco or a tobacco blend that is chewed
or sucked on rather than smoked, the main types
being chewing tobacco and snuff [74]. Smokeless
tobacco consistently produces levels of nicotine
higher than those seen with smoking [75]. Acute
cardiovascular effects, similar to those caused by
cigarette smoking, are seen with the use of smoke-
less tobacco, including coronary vasoconstriction
and increase in heart rate and cardiac output
[76]. Smokeless tobacco extract has been shown
to be more toxic in vitro than pure nicotine and
to increase oxidative stress as a result of reactive
oxygen free radicals [77]. However, there is con-
flicting evidence from prospective and case–control
studies about cardiovascular mortality or myocar-
dial infarction caused by smokeless tobacco use.
The INTERHEART (A Study of Risk Factors
for First Myocardial Infarction in 52 Countries
and Over 27,000 Subjects) showed that there was
an increased risk of nonfatal myocardial infarctions
among tobacco chewers, though relatively lesser
than for smokers [78]. The INTERHEART
investigators also found that the highest increase
in risk of acute myocardial infarction was in smok-
ers who also chewed tobacco.
Smoked tobacco products. Smoked noncigarette
forms of tobacco such as bidis, pipes, cigars, and
waterpipes are quite popular in some parts of the
world. They are often mistakenly perceived as less
hazardous than cigarettes, when in fact their health
risks are similar [79]. Pipe and cigar smokers, com-
pared with nonsmokers, have been shown to have a
significantly high risk of major coronary events
[80]. In fact, cigar smoke contains higher concen-
trations of toxic and carcinogenic compounds than
cigarettes do [81]. Bidi smoking, common in the
Indian subcontinent, delivers three times the
amount of carbon monoxide and nicotine and five
times the amount of tar as cigarette smoke does
[82]. The few studies that have looked at the car-
diovascular effects of bidi smoking reveal that bidi
smokers have an increased risk of CAD [83,84].
Data on waterpipe smoking and its cardiovascular
effects are limited.
‘‘Light’’ cigarettes, owing to the lower nicotine
and tar content, would be believed to be less harm-
ful than smoking regular cigarettes. However,studies have shown that smoking ‘‘light’’ cigarettes
impairs the coronary flow velocity reserve as
severely as smoking regular cigarettes does
[85].S E CONDHAND SMOK E
Exposure to secondhand smoke (environmental to-
bacco smoke, passive smoking) has been shown to
pose a similar health risk as that caused by direct
smoking. Approximately 40,000 deaths from heart
disease are estimated to be due to exposure to sec-
ondhand smoke each year in the United States
[86], reflecting the increased risk in nonsmokers
of death due to CAD by approximately 20% in
large epidemiologic studies [87]. The U.S. Surgeon
General, in the 2006 report, estimated that living
or working in a place where smoking is permitted
increases the nonsmokers’ risk of developing
CAD by 25–30% and lung cancer by 20–30%
[12]. In fact, legislations banning smoking in pub-
lic places have been shown to significantly decrease
the incidence of admissions of myocardial infarc-
tion [88]. Pell et al. [89] demonstrated that
smoke-free legislation decreased the number of
acute coronary syndromes in Scotland, and 67%
of this decrease involved nonsmokers. It has been
shown that exposure to secondhand smoke in
healthy young volunteers compromises coronary
artery endothelial function in a manner that is
indistinguishable from that of active smokers, sug-
gesting that endothelial dysfunction may be an
important mechanism by which secondhand smoke
increases CAD risk [90].TH I RDHAND SMOKE
The term ‘‘thirdhand smoke’’ has been recently
coined to identify the residual tobacco smoke con-
tamination that remains after the cigarette is extin-
guished and secondhand smoke has cleared from
the air [91,92]. It refers to the concept of contam-
ination of surfaces by components of tobacco
smoke. Among the substances in thirdhand smoke
are hydrogen cyanide, butane, toluene, arsenic,
lead, carbon monoxide, and polonium-210, most
of which may have carcinogenic potential. Preli-
minary research suggests that by-products of third-
hand smoke may pose a health risk [93], though
the magnitude of risk and effect on cardiovascular
system, if any, remains unknown.
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Cigarette smoking is a leading preventable risk fac-
tor for the development and progression of cardio-
vascular disease. Tobacco exerts its deleterious
cardiovascular effects through multiple mecha-
nisms. Endothelial dysfunction, increased oxidative
stress, and induction of a hypercoagulable state ap-
pear to be the key pathobiologic mechanisms in-
volved. Apart from direct smoking, secondhandsmoke has also been proven to be causally associ-
ated with an increased risk of CAD among non-
smokers. Clinical and experimental studies have
shown that the cardiovascular risk posed by smok-
ing reverses after smoking cessation. This empha-
sizes the importance of a comprehensive
antitobacco campaign, comprising individual-based
behavioral and pharmacological interventions to
fight nicotine addiction and community-level mea-
sures, as an important public health intervention.R E F E R E N C E S1. Hammond EC, Horn D. Smoking
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